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INTRODUCTION
H2-receptor antagonists inhibit histamine action on gastric pa-
rietal cells, thus decreasing acid production. Such therapy is usu-
ally indicated for the treatment of peptic ulcers and gastro-esoph-
ageal reflux disease. These agents are typically well-tolerated, 
and severe hypersensitivity reactions are extremely rare.
1 Here, 
we report two cases of severe hypersensitivity reactions induced 
by H2-receptor antagonists and possible cross-reactivities between 
drugs of this class.
 
CASE REPORT
Case 1
A 42-year-old female visited our clinic having recently suffered 
two episodes of angioedema. About 1 month earlier, she devel-
oped dyspnea, sneezing, and swelling of the eyelids 30 min af-
ter taking a single 150 mg ranitidine tablet (Zantac
®, GlaxoSmith-
Kline, Brentford, UK). One week later she again took ranitidine 
(Zantac
®) for dyspepsia, and once more developed the allergic 
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reactions immediately afterwards. She had dermographism and 
a history of skin rash in response to penicillins and sulfonamides. 
Her father was also allergic to penicillins, and her son suffered 
from asthma.
Based on her clinical history and the timing of the reactions, 
ranitidine-induced hypersensitivity was suspected. Due to se-
vere dermographism, the patient was unable to undergo skin 
tests; a direct challenge was performed instead. No positive re-
sponse was provoked to either placebo or 75 mg ranitidine 
(Curan
®, Il-Dong pharmaceuticals, Seoul, Korea) 30 min after 
oral challenge. However, the patient began to complain of rhi-
norrhea and generalized pruritus 30 min after administration 
of 150 mg ranitidine. On examination, urticaria was found in 
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H2-receptor antagonists, such as cimetidine, ranitidine and famotidine, are some of the most commonly prescribed medications for gastric acid-re-
lated disorders. These compounds are generally well-tolerated and anaphylactic reactions to them are rare. Here, we report two cases of H2-recep-
tor antagonist-induced anaphylactic reactions: the first presented with sudden dyspnea, sneezing, urticaria, and swelling of the eyelids after raniti-
dine intake. The second presented with sudden severe urticaria, facial swelling, chest discomfort, dizziness, and hypotension. Possible cross-reactiv-
ity with other H2-receptor antagonists was assessed by oral challenge and skin tests. To date, only a few reports addressing cross-reactivity among 
H2-receptor antagonists have been published. We review the literature and summarize the data available on drug cross-reactivity in H2-receptor an-
tagonist hypersensitivity.
Key Words:  Histamine H2 receptor antagonists; cross reactions; drug hypersensitivity; allergy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Correspondence to:  Yoon-Seok Chang, MD, PhD, Department of Internal 
Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, 
Bundang-gu, Seongnam 463-802, Korea.
Tel: +82-31-787-7023; Fax: +82-31-787-4052; E-mail: addchang@snu.ac.kr
Received: June 4, 2010; Accepted: August 10, 2010
•There are no financial or other issues that might lead to conflict of interest.H2 Blocker Anaphylaxis With Cross-Reactivity AAIR 
Allergy Asthma Immunol Res. 2011 April;3(2):128-131.  doi: 10.4168/aair.2011.3.2.128 129 http://e-aair.org
the axilla and ears. No significant change in FEV1 or blood pres-
sure was observed. The test was stopped and the symptoms treat-
ed with methylprednisolone and chlorpheniramine.
One month later, another challenge was performed with famoti-
dine (Gaster
®, Astellas Pharma Inc., Tokyo, Japan). Thirty min-
utes after challenge with 10 mg, the patient reported itching 
and a hot sensation in the palms. Because we decided that these 
symptoms were non-specific, we proceeded with a challenge 
using 20 mg famotidine. Ten minutes after ingesting, she began 
to complain of not only itching of the palms, but also sudden 
sneezing and rhinorrhea. The test was immediately stopped, 
and symptoms subsided spontaneously without progression. 
As a result, we concluded that this patient was allergic to raniti-
dine and famotidine. Thus, we diagnosed this case as ranitidine-
induced hypersensitivity reaction with possible cross-reactivity 
to famotidine.
Case 2
An 80-year-old male was transferred to the emergency room 
due to chest discomfort and dizziness. On arrival, his blood pres-
sure was 60/40 mmHg and he was wheezing. He looked con-
fused, and had a swollen face and severe generalized urticaria. 
He recovered after immediate administration of epinephrine, 
systemic corticosteroids, and chlorpheniramine. He was found 
to have taken chlorpheniramine, acetaminophen, and cimeti-
dine 10 min before the onset of his symptoms because of mild 
urticaria, which allegedly developed after pork intake. Immedi-
ately after taking these medications, he developed severe gen-
eralized urticaria, facial swelling, chest discomfort, dyspnea, and 
dizziness.
He suffered from asthma and angina pectoris, and was taking 
inhaled budesonide/formoterol, nitrate, carvedilol, nicorandil 
and triflusal. He had no other medical history, known adverse 
drug reactions, or relevant family history. Initial tests, including 
cardiac enzymes and an electrocardiogram, revealed no remark-
able abnormalities. Two weeks after recovery, a skin prick test 
was performed for common inhalant and food allergens, includ-
ing pork. These revealed weak skin positivity to only willow, tim-
othy and meadow, but no response to pork.
One month later, because this patient had suffered ischemic 
heart disease we performed skin instead of oral tests. Three com-
monly used H2-receptor antagonists were prepared: cimetidine 
(100 mg/mL), ranitidine (25 mg/mL), and famotidine (10 mg/
mL). The patient did not respond to any of the H2-receptor an-
tagonists. Subsequently, intradermal skin tests using cimetidine, 
ranitidine, and famotidine at 1:10,000, 1:1,000, and 1:100 dilu-
tions in NaCl were performed. If no response was observed, the 
concentration was increased in ten-fold steps. Cimetidine be-
gan to provoke a response at a 1:100, and ranitidine and famoti-
dine at a 1:10 dilution (Table 1). No systemic response was ob-
served.
Later, we identified acetaminophen to be safe to take orally. 
Chlorpheniramine was found to be safe after it was well-toler-
ated when accidentally injected in an emergency room. As a re-
sult, this case was diagnosed as cimetidine-induced anaphylax-
is with possible cross-reactivity with famotidine and ranitidine.
 
DISCUSSION
The discovery of specific H2-receptor antagonists in the 1970s 
revolutionized the management of gastric acid-related disorders. 
Cimetidine, the oldest and most used H2-receptor antagonist, 
inhibits many isozymes of the cytochrome P450 enzyme system.
2 
Thus, this agent has a higher risk of drug interactions than new-
er H2-receptor antagonists. Ranitidine, introduced in 1981, was 
designed by replacing the imidazole ring of cimetidine with a 
furan ring. Ranitidine has only 10% of the affinity to CYP450 of 
cimetidine.
3 Famotidine, developed in 1985, was structured by 
substituting the imidazole ring with a 2-guanidinothiazole ring. 
It does not bind to CYP450, and so has not been associated with 
significant interactions.
4
Apart from the known interactions of cimetidine, H2-receptor 
antagonists are generally well-tolerated. Severe hypersensitivity 
reactions are rare.
1,5-11 According to the Uppsala Monitoring Cen-
ter database for May 1999, the incidence of anaphylaxis repre-
sented 0.2-0.7% of all the reported adverse reactions to both H2-
receptor antagonists and proton pump inhibitors.
9
Direct challenge is considered the gold standard for diagnosis 
of drug allergies. However, performance of a direct challenge to 
a patient is often difficult, due to potential fatalities or unknown 
underlying diseases. In such cases, a skin or in vitro test can be 
helpful. In this report, we performed skin tests in the second case 
due to the risks arising from his cardiac conditions. It is some-
times problematic to distinguish true reactions from false posi-
tivity in intradermal tests. According to the literature, however, 
in normal controls skin irritation was not provoked at the most 
commonly used doses (20 mg/mL for famotidine, 75 mg/mL 
for ranitidine, and 150 mg/mL for cimetidine).
1 In this case, the 
minimum concentrations that provoked a response were: 1 mg/ 
mL, 2.5 mg/mL and 1 mg/mL, respectively, indicating true pos-
itivity.
Interestingly, both cases showed cross-reactivity with other H2-
Table 1.  Results of intradermal skin tests for cimetidine, famotidine, and ranit-
idine
Drug 1:10,000 1:1,000 1:100 1:10 1:1*
Cimetidine 0×0/0×0
† 0×0/0×0 6×6/28×34 7×7/30×35 8×8.5/40×40
Famotidine - - 0×0/0×0 5×8/22×22 6×8/25×35
Ranitidine - - 0×0/0×0 2×3/10×12 6×8.5/18×20
Saline - - - - 0×0/0×0
*Concentrations used were: cimetidine, 100 mg/mL; famotidine, 10 mg/mL; and
ranitidine, 25 mg/mL.
†Data are expressed as increased wheal diameter (mm×mm)/flare diameter 
(mm×mm).Song et al.
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receptor antagonists. So far, only a few reports of this phenome-
non have been published. We have summarized the literature 
published to date (Table 2). All of the cross-reactions were be-
tween famotidine and ranitidine or nizatidine, but none with 
cimetidine.
1,9,12,13 This may be due to the differences between ci-
metidine and other H2-receptor antagonists in terms of their side 
chain and ring structures. Ranitidine, nizatidine, and famotidine, 
but not cimetidine, share similar side chains on the ring struc-
tures (Figure).
12,13 This may explain the rarity of cross-reactions 
of cimetidine with other H2-receptor antagonists. To our knowl-
edge, this is the first report of possible cross-reactivity of cimeti-
dine with another H2-receptor antagonist.
An IgE-dependent mechanism has been suggested for anaphy-
laxis induced by H2-receptor antagonists, and rantidine-specific 
IgE antibody has been isolated from one case.
8
In summary, we report two cases of H2-receptor antagonist hy-
persensitivity reactions, showing possible cross-reactivity within 
the class. The first case was ranitidine hypersensitivity showing 
cross-reactivity with famotidine, as determined by oral challenge 
tests. The second case was of cimetidine-induced anaphylaxis, 
together with possible cross-reactivity to ranitidine and famoti-
dine, as determined by skin tests.
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